Inosine pranobex
Based on 1 publication(s) in Google Scholar
Inosine pranobex is an orally active immunomodulator. Inosine pranobex has broad-spectrum antiviral activity. Inosine pranobex inhibits human immunodeficiency virus (HIV), herpes simplex virus (HSV), vaccinia virus (VACV), human tumor virus (HPV), Cytomegalovirus, influenza virus (INFV), parainfluenza virus (PIV), and Epstein-Barr virus
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.59%
- CAS. Nr.: 36703-88-5
- Formel: C52H78N10O17
- Molecular Weight:1115.23
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Inosine pranobex
More
Customer Validation & Images
-
WB
Biologische Aktivität
Beschreibung
In Vitro
Inosine pranobex (50-200 mg/L; 24-72 h) significantly increases the secretion of TNF-α and IFN-γ (72 h) in lymphocytes, and inhibites IL-10 stimulated by PHA (5 mg/L) to produce lymphocytes, showing immunomodulatory properties[2].
Inosine pranobex (50-800 μg/mL; 48 h) can reduce the titer of HAdV-2 (IC50=1743.8 μg/mL) and HAdV-5 (IC50=1304.5 μg/mL) in A549 cells, and strongly inhibit the proliferation of the virus at high concentrations[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 36703-88-5
-
Appearance Solid
-
Molecular Weight 1115.23
-
Formel C52H78N10O17
-
Color White to off-white
-
SMILES
CC(NC1=CC=C(C(O)=O)C=C1)=O.CC(NC2=CC=C(C(O)=O)C=C2)=O.CC(O)CN(C)C.O[C@H]3[C@@H](O[C@H](CO)[C@H]3O)N4C5=C(C(N=CN5)=O)N=C4.CC(O)CN(C)C.CC(O)CN(C)C.CC(NC6=CC=C(C(O)=O)C=C6)=O
-
Synonyms
Imunovir; Delimmun; Groprinosin
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Viruses
Inhibition of Rabies Virus by 1,2,3,4,6-Penta- O-galloyl-β-d-Glucose Involves mTOR-Dependent Autophagy. [Abstract]2018 Apr 17;10(4):201. PMID: 29673174
Inosine pranobex purchased from MedChemExpress. Usage Cited in: Viruses. 2018 Apr 17;10(4):201. [Abstract]
After incubation with PGG and IPS, RABV is inoculated with BHK-21 cells for 48 h, and the expression level of viral P is analyzed by Western blotting.
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 62.5 mg/mL (56.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (1.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (1.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8967 mL | 4.4834 mL | 8.9668 mL | 22.4169 mL |
| 5 mM | 0.1793 mL | 0.8967 mL | 1.7934 mL | 4.4834 mL | |
| 10 mM | 0.0897 mL | 0.4483 mL | 0.8967 mL | 2.2417 mL | |
| 15 mM | 0.0598 mL | 0.2989 mL | 0.5978 mL | 1.4945 mL | |
| 20 mM | 0.0448 mL | 0.2242 mL | 0.4483 mL | 1.1208 mL | |
| 25 mM | 0.0359 mL | 0.1793 mL | 0.3587 mL | 0.8967 mL | |
| 30 mM | 0.0299 mL | 0.1494 mL | 0.2989 mL | 0.7472 mL | |
| 40 mM | 0.0224 mL | 0.1121 mL | 0.2242 mL | 0.5604 mL | |
| 50 mM | 0.0179 mL | 0.0897 mL | 0.1793 mL | 0.4483 mL |
Inosine pranobex Related Classifications
HY-107801 Related Classifications
Powered by Bioz